Wall Street Journal |
New Question for Drivers: Organ Donor?
Wall Street Journal The new line on driver’s license applications will ask people whether they want to be added to the organ donor registry by selecting either “yes” or “skip this question,” an effort to improve organ-donation rates, which in New York lag behind the rest … Legalize Murder for Organs?National Review Online (blog) |
NICE backs Roche's MabThera in rare autoimmune disease – PMLiVE
|
NICE backs Roche’s MabThera in rare autoimmune disease
PMLiVE The draft guidance overturns an earlier decision made by NICE which failed to recommend the use of MabThera (rituximab) for NHS use in England and Wales to treat anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis – an inflammation of the … Roche’s MabThera now favoured by NICE in vasculitisPharmaTimes |
Cellmid's midkine antibodies show effectiveness against cancer – Proactive Investors Australia
Proactive Investors Australia |
Cellmid’s midkine antibodies show effectiveness against cancer
Proactive Investors Australia “We have postulated for some time that MK antibodies would have anti-cancer activities, via multiple mechanisms of action, and it is pleasing to see this confirmed in our own studies with our proprietary MK antibodies.” Cellmid’s cancer antibody … |
Studies from University of Pisa Reveal New Findings on Lymphoma – HispanicBusiness.com
Studies from University of Pisa Reveal New Findings on LymphomaHispanicBusiness.comAmong different possible chemotherapeutic approaches, purine analogs, alone or in association with Rituximab, seem to be a valid therapeutic choice. Fifty SMZL patients …
New Lymphoma Study Findings Recently Were Reported by Researchers at … – HispanicBusiness.com
|
New Lymphoma Study Findings Recently Were Reported by Researchers at …
HispanicBusiness.com Twenty-four patients were enrolled prospectively and were treated with unlabeled rituximab 70 mg and a therapeutic activity (median 7.3 GBq) of I-131 –rituximab.” The news correspondents obtained a quote from the research from the Institute of … |
Study Findings from Shanghai Jiao-Tong University Provide New Insights into … – HispanicBusiness.com
Study Findings from Shanghai Jiao-Tong University Provide New Insights into …HispanicBusiness.comThe effect of rituximab alone or combined with the PI3K/AKT/mTOR pathway inhibitor rapamycin was further evaluated in the DLBCL cell lines. A total of 73…
Researchers at Department of Haematology and Oncology Report Findings in … – HispanicBusiness.com
|
Researchers at Department of Haematology and Oncology Report Findings in …
HispanicBusiness.com Their experience showed that this drug is effective and manageable even when reused in both settings: chronic lymphocytic leukemia and non-Hodgkin’s lymphomas combined with rituximab and/or mitoxantrone. The slow evolution in the treatment of patients … |
FDA Product Safety News – SCVNEWS.com
FDA Product Safety NewsSCVNEWS.comMore informationDrug Safety Communication: Boxed Warning and new recommendations to decrease risk of hepatitis B reactivation with the immune-suppressing and anti-cancer drugs Arzerra (ofatumumab) and Rituxan (rituxima…
From 16-year-old, inspiring lesson in life – Times of India
|
From 16-year-old, inspiring lesson in life
Times of India The girl from Belur in Howrah was born with Marfin’s Syndrome, a connective tissue disorder. By age 14 the disease had affected her heart, lungs, retina and spine. She lost vision in her left eye and an aortic root dilation had swelled her heart to … |
CRSA Committed to Advancing Surgeon Training in Robotic Surgery – EON: Enhanced Online News (press release)
|
CRSA Committed to Advancing Surgeon Training in Robotic Surgery
EON: Enhanced Online News (press release) This technology has dramatically improved the utilization of minimally invasive surgery across several fields including urology, gynecology, thoracic, cardiac, colon, pancreas and transplant surgery. “As robotic surgery continues to evolve, it is … |